TELO Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Telomir Pharmaceuticals Inc | Needs refresh | Last updated: 2026-04-23T10:26:17Z

TickerTELO

Market Cap47.1M

Cash RunwayRunway 6-12 months

Next Catalyst2027-05

Public Research Snapshot

Telomir Pharmaceuticals Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Targeting Metal-Dependent Epigenetic Dysregulation.

Pipeline

Asset	Indication	Modality	Stage	Public Note
Targeting Metal-Dependent Epigenetic Dysregulation	n/a	n/a	n/a	Public pipeline row
Zn-Telomir	n/a	n/a	Phase 1 \| Phase 2	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2027-05	Zn-Telomir	Low

Cash Runway Preview

Estimated cash runway: Runway 6-12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT07581314	Phase 1 \| Phase 2	NOT_YET_RECRUITING	76	2027-05

Scientific Context

indication | any disease or condition
indication | any disease or condition
mechanism | designed to combat the fundamental drivers of aging and chronic disease. By regulating essential metals like iron and copper, extending and protecting telomere caps, and d
mechanism | designed to combat the fundamental drivers of aging and chronic disease. By regulating essential metals like iron and copper, extending and protecting telomere caps, and d
modality | small molecule

Want the full TELO research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.